Identification of nuclear protein targets for six leukemogenic tyrosine kinases governed by post-translational regulation

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Pierce, Andrew ^a   Williamson, Andrew ^a   Jaworska, Ewa ^a   Griffiths, John R ^a   Taylor, Sam ^a   Walker, Michael ^a   O'Dea, Mark Aspinall ^a   Spooncer, Elaine ^a   Unwin, Richard D ^a   Poolman, Toryn ^a   Ray, David ^a   Whetton, Anthony D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; FIP1L PDGFRALPHA FUSION PROTEIN; FLT3ITD PROTEIN; GLUCOCORTICOID RECEPTOR; HYBRID PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KIT D816V FUSION PROTEIN; MESSENGER RNA; MISMATCH REPAIR PROTEIN PMS2; NMP ALK FUSION PROTEIN; ONCOPROTEIN; TEL PDGFRBETA FUSION PROTEIN; TIOGUANINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL LEVEL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOPLASM; FUNCTIONAL PROTEOMICS; GENE ACTIVATION; LEUKEMOGENESIS; MISMATCH REPAIR; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING;

ANIMALS; CELL LINE; MASS SPECTROMETRY; MICE; NUCLEAR PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; PROTEOMICS; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84862648509     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038928     Document Type: Article

References (53)

1. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, et al. (1995) Anaplastic Large-Cell Lymphomas expressing the novel chimeric protein P80(NPM/ALK)- A distinct clinicopathological entity Blood 86: 1954-1960.
2. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, et al. (1993) Identification of mutations in the coding sequence of the protooncogene c-Kit in a human Mast-cell Leukemia-cell line causing ligand-independent activation of c-kit product Journal of Clinical Investigation 92: 1736-1744.
3. Shtivelman E, Lifshitz B, Gale RP, Canaani E, (1985) Fused transcript of ABL and BCR genes in Chronic Myelogenous Leukemia Nature 315: 550-554.
4. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG, (2004) The FIP1L1-PDGFR alpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Current Opinion in Hematology 11: 51-57.
5. Golub TR, Barker GF, Lovett M, Gilliland DG, (1994) Fusion of PDGF Receptor-Beta to a novel ETS-like gene, TEL, in Chronic Myelomonocytic Leukemia with T(512) chromosomal translocation Cell 77: 307-316.
6. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, et al. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98: 1752-1759.
7. Dobbin E, Graham C, Corrigan PM, Thomas KG, Freeburn RW, et al. (2009) Tel/PDGFR beta induces stern cell differentiation via the Ras/ERK and STAT5 signaling pathways. Experimental Hematology 37: 111-121.
8. Skorski T, (2002) BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 21: 8591-8604.
9. Canitrot Y, Lautier D, Laurent G, Frechet M, Ahmed A, et al. (1999) Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene 18: 2676-2680.
10. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, et al. (2005) Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 105: 1717-1723.
11. Rink L, Slupianek A, Stoklosa T, Nieborowska-Skorska M, Urbanska K, et al. (2007) Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood 110: 651-660.
12. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, et al. (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701-4707.
13. Lu R, Markowetz F, Unwin RD, Leek JT, Airoldi EM, et al. (2009) Systems-level dynamic analyses of fate change in murine embryonic stem cells. Nature 462: 358-U126.
14. Pierce A, Unwin RD, Evans CA, Griffiths S, Carney L, et al. (2008) Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Molecular & Cellular Proteomics 7: 853-863.
15. Thanos D, Maniatis T, (1992) The High Mobility Group protein HMG I(Y) is required for NF-κB-dependent virus induction of the human IFN-β gene. Cell 71: 777-789.
16. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB, (2011) NF-kappa B addiction and its role in cancer: 'one size does not fit all'. Oncogene 30: 1615-1630.
17. Iervolino A, Santilli G, Trotta R, Guerzoni C, Cesi V, et al. (2002) hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Molecular and Cellular Biology 22: 2255-2266.
18. Hamilton MJ, Ho VW, Kuroda E, Ruschmann J, Antignano F, et al. (2010) Role of SHIP in cancer. Experimental Hematology 39: 2-13.
19. Ward IM, Minn K, van Deursen J, Chen JJ, (2003) p53 binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Molecular and Cellular Biology 23: 2556-2563.
20. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PNG, et al. (2009) Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes. Molecular Cell 36: 326-339.
21. Hoyer-Hansen M, Jaattela M, (2008) Autophagy- An emerging target for cancer therapy. Autophagy 4: 574-580.
22. Costoya JA, Hobbs RM, Pandolfi PP, (2008) Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation. Oncogene 27: 3789-3796.
23. Park I-k, Qian D, Kiel M, Becker MW, Pihalja M, et al. (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302-305.
24. Tsuzuki S, Enver T, (2002) Interactions of GATA-2 with the promyelocytic leukemia zinc finger (PLZF) protein, its homologue FAZF, and the t(11;17)-generated PLZF-retinoic acid receptor alpha oncoprotein. Blood 99: 3404-3410.
25. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, et al. (2010) TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463: 676-680.
26. Yu YL, Chiang YJ, Yen JJY, (2002) GATA factors are essential for transcription of the survival gene E4bp4 and the viability response of interleukin-3 in Ba/F3 hematopoietic cells. Journal of Biological Chemistry 277: 27144-27153.
27. Pierantoni GM, Agosti V, Fedele M, Bond H, Caliendo I, et al. (2003) High-mobility group A1 proteins are overexpressed in human leukaemias. Biochemical Journal 372: 145-150.
28. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, et al. (2003) Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Molecular and Cellular Biology 23: 2225-2238.
29. Resar LMS, (2010) The High Mobility Group A1 Gene: Transforming Inflammatory Signals into Cancer? Cancer Research 70: 436-439.
30. Shimizu Y, Iwai S, Hanaoka F, Sugasawa K, (2003) Xeroderma pigmentosum group C protein interacts physically and functionally with thymine DNA glycosylase. Embo Journal 22: 164-173.
31. Foti D, Iuliano R, Chiefari E, Brunetti A (2003) A nucleoprotein complex containing sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. Molecular and Cellular Biology 23: 2720-2732.
32. Treff NR, Dement GA, Adair JE, Britt RL, Nie R, et al. (2004) Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells. Oncogene 23: 8557-8562.
33. Wang Z, Frederick J, Garabedian MJ, (2002) Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo. Journal of Biological Chemistry 277: 26573-26580.
34. Kolbus A, Blazquez-Domingo M, Carotta S, Bakker W, Luedemann S, et al. (2003) Cooperative signaling between cytokine receptors and the glucocorticoid receptor in the expansion of erythroid progenitors: molecular analysis by expression profiling. Blood 102: 3136-3146.
35. Greenberger JS, (1978) Sensitivity of corticosteroid-dependent insulin-resistance lipogenesis in marrow preadipocytes of obese diabetic (DB-DB) mice Nature 275: 752-754.
36. Inaba H, Pui C-H, (2010) Glucocorticoid use in acute lymphoblastic leukaemia. The Lancet Oncology 11: 1096-1106.
37. Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E, (2008) Mechanisms Regulating the Susceptibility of Hematopoietic Malignancies to Glucocorticoid-Induced Apoptosis. In: VandeWoude GFKG, editors. editor. Advances in Cancer Research, Vol 101. 127-+.
38. Barnes PJ, Adcock IM, (2009) Glucocorticoid resistance in inflammatory diseases. The Lancet 373: 1905-1917.
39. Munkholm P, Langholz E, Davidsen M, Binder V, (1994) Frequency of Glucocorticoid resistance and dependency in Crohns-disease Gut 35: 360-362.
40. Tissing WJE, Meijerink JPP, den Boer ML, Pieters R, (2003) Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 17: 17-25.
41. Mao GG, Yuan FH, Absher K, Jennings CD, Howard DS, et al. (2008) Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression. Cell Research 18: 281-289.
42. Lynch HT, de la Chapelle A, (1999) Genetic susceptibility to non-polyposis colorectal cancer. Journal of Medical Genetics 36: 801-818.
43. Clendenning M, Senter L, Hampel H, Robinson KL, Sun S, et al. (2008) A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. Journal of Medical Genetics 45: 340-345.
44. De Vos M, Hayward BE, Charlton R, Taylor GR, Glaser AW, et al. (2006) PMS2 mutations in childhood cancer. Journal of the National Cancer Institute 98: 358-361.
45. Chen J, Sadowski I, (2005) Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proceedings of the National Academy of Sciences of the United States of America 102: 4813-4818.
46. Dobrovolsky VN, McKinzie PB, Shaddock JG, Mittelstaedt RA, Heflich RH, et al. (2003) Pms2 deficiency results in increased mutation in the Hprt gene but not the Tk gene of Tk(+/-) transgenic mice. Mutagenesis 18: 365-370.
47. Narayanan L, Fritzell JA, Baker SM, Liskay RM, Glazer PM, (1997) Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2. Proceedings of the National Academy of Sciences of the United States of America 94: 3122-3127.
48. Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, et al. (2007) FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J 26: 2104-2114.
49. Anderson L, Henderson C, Adachi Y, (2001) Phosphorylation and Rapid Relocalization of 53BP1 to Nuclear Foci upon DNA Damage. Mol Cell Biol 21: 1719-1729.
50. Karisch R, Fernandez M, Taylor P, Virtanen C, St-Germain Jonathan R, et al. (2011) Global Proteomic Assessment of the Classical Protein-Tyrosine Phosphatome and "Redoxome" Cell 146: 826-840.
51. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, et al. (2000) The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells. Journal of Biological Chemistry 275: 24273-24278.
52. Palacios R, Steinmetz M, (1985) IL3-dependent mouse clones that express B-220 surface antigen, contain ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41: 727-734.
53. MacArthur BD, Lachmann A, Lemischka IR, Ma'ayan A, (2010) GATE: software for the analysis and visualization of high-dimensional time series expression data. Bioinformatics 26: 143-144.